Mivacurium Kalceks (Mivacurium)

Mivacurium works by competitively blocking nicotinic acetylcholine receptors at the motor end‑plate of skeletal muscle. This inhibition prevents acetylcholine‑mediated depolarization, stopping nerve impulse transmission and resulting in a dose‑dependent, reversible muscle relaxation.

The appropriate dose of Mivacurium Kalceks is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and the specific procedural requirements. Dosing guidelines are provided in the product label, but the final regimen is set by the treating physician.

Mivacurium is classified as pregnancy category unknown. It should be used during pregnancy or lactation only when the potential therapeutic benefit justifies any potential risk to the fetus or infant. Clinicians should assess the risk‑benefit ratio on an individual basis.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Mivacurium is a short‑acting, non‑depolarizing blocker that is rapidly hydrolyzed by plasma cholinesterases, leading to a quicker recovery compared with agents such as rocuronium or vecuronium. Its rapid offset makes it useful for brief procedures, whereas longer‑acting agents are preferred when prolonged muscle relaxation is needed.

Mivacurium Kalceks should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use the product if the container is damaged or if the solution appears discolored.

Mivacurium is administered by intravenous injection. The clinician injects the prepared sterile solution directly into a vein, usually as a bolus dose followed by a continuous infusion if prolonged relaxation is required. Administration is performed under close monitoring of neuromuscular function and vital signs.

The most serious adverse events include anaphylaxis, which can be life‑threatening and requires immediate emergency treatment, and prolonged apnea, where respiratory muscle paralysis persists longer than expected, necessitating assisted ventilation. Severe hypotension and cardiac arrhythmias are also rare but critical complications.

Mivacurium should be avoided in patients with a known hypersensitivity to the drug or to other non‑depolarizing neuromuscular blockers. Caution is advised in individuals with severe hepatic or renal impairment, as well as in patients with conditions that predispose them to malignant hyperthermia or significant cardiovascular instability.